Mark Lustberg, PhD, MD
Associate Professor of Internal Medicine (Infectious Diseases)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
Infectious Diseases
300 Cedar St, TAC
New Haven, Connecticut 06519
United States
About
Copy Link
Titles
Associate Professor of Internal Medicine (Infectious Diseases)
Appointments
Infectious Diseases
Associate Professor on TermPrimary
Other Departments & Organizations
- Cancer-Infectious Diseases (Cancer-ID) Program
- Infectious Diseases
- Internal Medicine
- Yale Medicine
- Yale New Haven Health System
Education & Training
- MD
- University of Maryland School of Medicine, Internal Medicine Infectious Diseases (2004)
- PhD
- University of Maryland Baltimore Graduate School, Epidemiology (2002)
- BS
- University of Maryland College Park, Biochemistry (1992)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mark Lustberg's published research.
Publications Timeline
A big-picture view of Mark Lustberg's research output by year.
Maryam Lustberg, MD, MPH
Brian Clark, MD
34Publications
665Citations
Publications
2026
Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease
Weigel C, Klimaszewski H, Tounkara F, Addissie S, Schlotter S, Pray B, Dugan J, Haverkos B, Villagomez L, Lustberg M, Porcu P, Voorhees T, Ambinder R, Kenney S, Fingeroth J, Delecluse H, Caligiuri M, Alinari L, Bumgardner G, Oakes C, Baiocchi R. Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease. Blood Neoplasia 2026, 3: 100200. PMID: 41808730, PMCID: PMC12969294, DOI: 10.1016/j.bneo.2026.100200.Peer-Reviewed Original ResearchCitationsAltmetricConceptsRapid amplificationEpigenetic activationPromoter activityComplimentary DNADNA methylation lossTranscription start siteViral protein kinaseRNA expression analysisPTLD casesLymphoproliferative diseaseStart siteCpG dinucleotidesActive demethylationDNA methylationLong-term clinical outcome dataEBV-infected cell linesEpigenetic basisGene promoterMethylation levelsProtein kinaseExpression analysisSystemic lymphoproliferative diseaseClinical outcome dataLuciferase reporter analysisPromoter methylation
2025
Anti-IL-5 Treatment Reduces Infection-Related Adverse Events: A Meta-Analysis of Phase 3 Clinical Trials
Lustberg M, Clark B. Anti-IL-5 Treatment Reduces Infection-Related Adverse Events: A Meta-Analysis of Phase 3 Clinical Trials. The Journal Of Allergy And Clinical Immunology In Practice 2025, 13: 1622-1631. PMID: 39947298, DOI: 10.1016/j.jaip.2025.01.037.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAnti-IL-5 therapyAnti-IL-5Lower respiratory tract infectionsPhase 3 clinical trialsRespiratory tract infectionsAdverse eventsTract infectionsPlacebo-controlled phase 3 clinical trialMeta-analysisInfection-related adverse eventsBacterial infectionsAnti-IL-5 treatmentC difficile infectionAssessment of adverse eventsClostridium difficile infectionPopulation of patientsInfectious diseasesInfluenza infectionMAb therapyDifficile infectionNon-serious eventsTherapyMultiple meta-analysesSerious eventsInfection
2024
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort
Nichols C, Lustberg M, Sobhanie M, Niermann L, Gordon M, Kman N, Parsons J, Conroy M, Dick M, Allen J, Reed E, Lehman J, Malvestutto C. Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort. Antiviral Therapy 2024, 29: 13596535241264694. PMID: 39066463, DOI: 10.1177/13596535241264694.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral AgentsCOVID-19COVID-19 Drug TreatmentDrug CombinationsEmergency Service, HospitalFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeConceptsMonoclonal antibody therapyFood and Drug AdministrationAntibody therapyClinical outcomesControl groupMild to moderate coronavirus diseasePost-COVID-19 diagnosisCOVID-19 diagnosisUntreated control cohortProgression to severe diseaseEmergency departmentHospital admissionDays of COVID-19 diagnosisDays post-diagnosisHigh-risk adultsED visitsModerate coronavirus diseaseLogistic regression analysisSingle-centerRetrospective studyClinical characteristicsMultivariate regression modelControl cohortOdds ratioDrug AdministrationA retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
McNally G, Aossey C, Wiczer T, Sinnott L, Lustberg M, Baiocchi R, Lustberg M. A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter? Leukemia & Lymphoma 2024, 65: 1110-1116. PMID: 38648546, DOI: 10.1080/10428194.2024.2340051.Peer-Reviewed Original ResearchCitationsAltmetricConceptsChemotherapy-induced peripheral neuropathyIncidence of chemotherapy-induced peripheral neuropathyHIV statusPeripheral neuropathyHIV-associated non-Hodgkin's lymphomaCohort studyDose-adjusted EPOCHNon-Hodgkin's lymphomaLong-term patient outcomesRetrospective cohort studyNon-HodgkinComprehensive cancer centerCancer CenterHIVPatientsNeuropathyPatient outcomesPropensity scoreLymphomaAdverse effectsIncidenceStatusRegimenVincristine
2023
Weight Gain in People with HIV: The Role of Demographics, Antiretroviral Therapy, and Lifestyle Factors on Weight
Patel Y, Doshi A, Levesque A, Lindor S, Moranville R, Okere S, Robinson D, Taylor L, Lustberg M, Malvestutto C. Weight Gain in People with HIV: The Role of Demographics, Antiretroviral Therapy, and Lifestyle Factors on Weight. AIDS Research And Human Retroviruses 2023, 39: 652-661. PMID: 37276145, DOI: 10.1089/aid.2023.0008.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIntegrase strand transfer inhibitorsFactors associated with weight gainAntiretroviral therapyRetrospective cohort studyTenofovir alafenamideOhio State University Wexner Medical CenterEffects of concurrent medicationsWeight gainStudy periodAntiretroviral therapy combinationsHistory of malignancyStrand transfer inhibitorsFollow-up periodWeight changeCombination therapyViral loadConcurrent medicationsWexner Medical CenterAdult PWHFollow-upMedical comorbiditiesPrimary outcomeMixed effects regression analysisSecondary outcomesTransfer inhibitorsFollicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein–Barr Virus Lymphoproliferative Disorder
Ahmed E, Lustberg M, Hale C, Sloan S, Mao C, Zhang X, Ozer H, Schlotter S, Smith P, Jeney F, Chan K, Harrington B, Weigel C, Brooks E, Klimaszewski H, Oakes C, Abebe T, Ibrahim M, Alinari L, Behbehani G, Shindiapina P, Caligiuri M, Baiocchi R. Follicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein–Barr Virus Lymphoproliferative Disorder. Cancers 2023, 15: 3046. PMID: 37297008, PMCID: PMC10252287, DOI: 10.3390/cancers15113046.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEBV-driven lymphoproliferative disordersPeripheral blood mononuclear cellsEpstein-Barr virusDonor peripheral blood mononuclear cellsRegulatory T cellsT cellsLymphoproliferative disordersAnalysis of CD4+ T cellsEngraftment of immunodeficient miceHealthy EBV-seropositive donorsMyeloid-derived suppressor cellsCD4+ T cellsEBV-seropositive donorsT follicular helperMemory B cellsInflammatory gene signatureLife-long persistenceBlood mononuclear cellsEBV+ donorsSuppressor cellsCTL proliferationEngrafted miceImmunocompromised patientsFollicular helperImmunodeficient mice
2022
Evidence Based Scarce Resource Allocation During the COVID-19 Pandemic: A Case Study of Bamlanivimab Administration in the Emergency Department
Rozycki E, Weiner A, Malvestutto C, Kman N, Lustberg M, Dick M, Lehman K, Schieber A, Luca L, Jordan T, Reed E, Allen J, Parsons J, Nichols C, Conroy M. Evidence Based Scarce Resource Allocation During the COVID-19 Pandemic: A Case Study of Bamlanivimab Administration in the Emergency Department. Hospital Pharmacy 2022, 57: 639-645. PMID: 36081532, PMCID: PMC9445538, DOI: 10.1177/00185787211073466.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMethods: PatientsEmergency departmentSymptom durationMedian numberReturn visitsAbnormal chest X-rayRisk factorsResults:Numbers of risk factorsProgression to severe diseaseMild to moderate COVID-19Median symptom durationChest X-rayAfrican American raceModerate COVID-19Abnormal CXRMedian timeClinical characteristicsClinical outcomesEligible patientsMultivariate regression modelAcademic medical centerObservational cohortMale genderPrimary outcomeEvaluation of central line salvage for mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) management practices in patients with hematologic malignancies
Boghdadly Z, Zhao Q, Koutou J, Lustberg M, Ludwig M, Liscynesky C, Choe H. Evaluation of central line salvage for mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) management practices in patients with hematologic malignancies. Leukemia & Lymphoma 2022, 63: 1455-1463. PMID: 35001802, DOI: 10.1080/10428194.2021.2020778.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsCVC salvageHematopoietic stem cell transplantationCentral venous catheterAllogeneic hematopoietic stem cell transplantationLaboratory-confirmed bloodstream infectionMucosal barrier injury laboratory-confirmed bloodstream infectionMBI-LCBIHematologic malignanciesBloodstream infectionsStem cell transplantationInfectious disease specialistsIn-Hospital MortalityLine salvageMicrobiological clearanceCell transplantationRecurrent infectionsVenous cathetersRetrospective studyBacterial translocationDisease specialistsCompare outcomesCancer CenterClinical scenariosResponse ratePatients
2021
Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients
Koenig K, Curley T, Mani S, Keiter A, Zhao Q, Behbehani G, Bhatnagar B, Blachly J, Haque T, Larkin K, Long M, Mims A, Vasu S, Wall S, Byrd J, Lustberg M, Walker A, Grieselhuber N. Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients. Hematological Oncology 2021, 40: 116-119. PMID: 34713477, DOI: 10.1002/hon.2941.Commentaries, Editorials and LettersCitationsAltmetricA Collaborative Intervention Between Emergency Medicine and Infectious Diseases to Increase Syphilis and HIV Screening in the Emergency Department
Lipps A, Bazan J, Lustberg M, Sobhanie M, Pollak B, Nandam K, Koletar S, Lindsey S, Dick M, Malvestutto C. A Collaborative Intervention Between Emergency Medicine and Infectious Diseases to Increase Syphilis and HIV Screening in the Emergency Department. Sexually Transmitted Diseases 2021, 49: 50-54. PMID: 34108412, PMCID: PMC8663525, DOI: 10.1097/olq.0000000000001496.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHIV testing ratesSexually transmitted infectionsHIV testingEmergency medicineEmergency departmentPostintervention periodTesting ratesHIV resultsFollow-up of positive resultsPositive syphilisHIV screeningPreintervention periodGonorrhea testingCollaborative interventionID providersMultidisciplinary teamPostinterventionIdentification of patientsInfectious diseasesRisk factorsHIVPreinterventionStudy objectiveStudy periodProviders
Clinical Care
Copy Link
Overview
Mark Lustberg, MD, PhD, is an infectious disease specialist who focuses on managing infectious diseases, including HIV and AIDS.
As an associate professor of internal medicine at Yale School of Medicine, Dr. Lustberg researches innovative strategies in the field of infectious diseases.
Dr. Lustberg earned his medical degree from the University of Maryland School of Medicine and a doctorate in epidemiology from the University of Maryland, Baltimore, Graduate School. He then furthered his training by completing a residency at York Hospital and a fellowship at Ohio State University Medical Center.
Clinical Specialties
Infectious Diseases; HIV & AIDs Medicine
Fact Sheets
Sepsis
Learn More on Yale MedicineParasitic Diseases
Learn More on Yale MedicinePediatric Sepsis
Learn More on Yale MedicineEndocarditis
Learn More on Yale Medicine
Board Certifications
Infectious Diseases
- Certification Organization
- American Board of Internal Medicine
- Latest Certification Date
- 2022
- Original Certification Date
- 2019
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileGet In Touch
Copy Link
Contacts
Appointment Number
Mailing Address
Infectious Diseases
300 Cedar St, TAC
New Haven, Connecticut 06519
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.